Globus Medical (NYSE:GMED) reports sales below analyst estimates in Q3 2026 earnings
Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, missing estimates by 3.6%, but adjusted EPS of $1.23 beat expectations. The company lowered full-year revenue guidance to $3.09B, a 3.4% decrease, while reaffirming adjusted EPS guidance of $5. Operating and free cash flow margins improved year over year.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to weigh on the stock, though margin expansion offers a partial offset.
Market read
The earnings release provides fresh material that can drive short‑term price action for GMED and may influence sentiment in the broader med‑tech space.
What to watch
Improved operating margin and free cash flow margin may offset revenue concerns for value‑focused investors.
Background
Globus Medical reported Q3 2026 results with revenue slightly below consensus and lowered full‑year revenue guidance.
Ticker impact
Q3 sales missed estimates and full-year revenue guidance was lowered to $3.09B.
likely pressure as the market prices in the revenue guidance cut
Both top-line miss and reduced guidance are fresh primary disclosures that typically trigger downside moves.
Market effects
Medical device sector may see broader scrutiny on growth forecasts.
U.S. healthcare stocks could face modest pullback.
Limited to investors tracking U.S. med‑tech equities.
Counterpoint
If the miss is viewed as a temporary setback, the stock could rebound on cost‑control improvements.
Key entities
- companyGlobus Medical
Medical device manufacturer listed on NYSE.
